The global Spinal Muscular Atrophy Medicine market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period.
Report Overview
This report provides a deep insight into the global Spinal Muscular Atrophy Medicine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Spinal Muscular Atrophy Medicine Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Spinal Muscular Atrophy Medicine market in any manner.
Global Spinal Muscular Atrophy Medicine Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- Astellas Pharma Inc.
- AveXis, Inc.
- Bioblast Pharma Ltd.
- Cytokinetics, Inc. 24
- F. Hoffmann-La Roche Ltd.
- Genethon
- Genzyme Corporation
- GMP-Orphan SAS
- Ionis Pharmaceuticals, Inc.
- Longevity Biotech, Inc
- Neurodyn Inc.
- Neurotune AG
- Novartis AG
- Sarepta Therapeutics, Inc.
- Voyager Therapeutics, Inc.
- Vybion, Inc.
- WAVE Life Sciences Ltd.
Market Segmentation (by Type)
- LMI-070
- ND-602
- NT-1654
- Nusinersen
- NXD-30001
- Others
Market Segmentation (by Application)
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Spinal Muscular Atrophy Medicine Market
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porters five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
Chapter Outline
Chapter 1 mainly introduces the statistical
scope of the report, market division standards, and market research methods.
Chapter 2 is an executive
summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Spinal Muscular Atrophy Medicine Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Spinal Muscular Atrophy Medicine
1.2 Key Market Segments
1.2.1 Spinal Muscular Atrophy Medicine Segment by Type
1.2.2 Spinal Muscular Atrophy Medicine Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Spinal Muscular Atrophy Medicine Market Overview
2.1 Global Market Overview
2.1.1 Global Spinal Muscular Atrophy Medicine Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Spinal Muscular Atrophy Medicine Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Spinal Muscular Atrophy Medicine Market Competitive Landscape
3.1 Global Spinal Muscular Atrophy Medicine Sales by Manufacturers (2019-2024)
3.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Manufacturers (2019-2024)
3.3 Spinal Muscular Atrophy Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Spinal Muscular Atrophy Medicine Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Spinal Muscular Atrophy Medicine Sales Sites, Area Served, Product Type
3.6 Spinal Muscular Atrophy Medicine Market Competitive Situation and Trends
3.6.1 Spinal Muscular Atrophy Medicine Market Concentration Rate
3.6.2 Global 5 and 10 Largest Spinal Muscular Atrophy Medicine Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Spinal Muscular Atrophy Medicine Industry Chain Analysis
4.1 Spinal Muscular Atrophy Medicine Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Spinal Muscular Atrophy Medicine Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Spinal Muscular Atrophy Medicine Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2019-2024)
6.3 Global Spinal Muscular Atrophy Medicine Market Size Market Share by Type (2019-2024)
6.4 Global Spinal Muscular Atrophy Medicine Price by Type (2019-2024)
7 Spinal Muscular Atrophy Medicine Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Spinal Muscular Atrophy Medicine Market Sales by Application (2019-2024)
7.3 Global Spinal Muscular Atrophy Medicine Market Size (M USD) by Application (2019-2024)
7.4 Global Spinal Muscular Atrophy Medicine Sales Growth Rate by Application (2019-2024)
8 Spinal Muscular Atrophy Medicine Market Segmentation by Region
8.1 Global Spinal Muscular Atrophy Medicine Sales by Region
8.1.1 Global Spinal Muscular Atrophy Medicine Sales by Region
8.1.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Region
8.2 North America
8.2.1 North America Spinal Muscular Atrophy Medicine Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Spinal Muscular Atrophy Medicine Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Spinal Muscular Atrophy Medicine Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Astellas Pharma Inc.
9.1.1 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Basic Information
9.1.2 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Overview
9.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Market Performance
9.1.4 Astellas Pharma Inc. Business Overview
9.1.5 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine SWOT Analysis
9.1.6 Astellas Pharma Inc. Recent Developments
9.2 AveXis, Inc.
9.2.1 AveXis, Inc. Spinal Muscular Atrophy Medicine Basic Information
9.2.2 AveXis, Inc. Spinal Muscular Atrophy Medicine Product Overview
9.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Product Market Performance
9.2.4 AveXis, Inc. Business Overview
9.2.5 AveXis, Inc. Spinal Muscular Atrophy Medicine SWOT Analysis
9.2.6 AveXis, Inc. Recent Developments
9.3 Bioblast Pharma Ltd.
9.3.1 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Basic Information
9.3.2 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Overview
9.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Market Performance
9.3.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine SWOT Analysis
9.3.5 Bioblast Pharma Ltd. Business Overview
9.3.6 Bioblast Pharma Ltd. Recent Developments
9.4 Cytokinetics, Inc. 24
9.4.1 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Basic Information
9.4.2 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Overview
9.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Market Performance
9.4.4 Cytokinetics, Inc. 24 Business Overview
9.4.5 Cytokinetics, Inc. 24 Recent Developments
9.5 F. Hoffmann-La Roche Ltd.
9.5.1 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Basic Information
9.5.2 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Overview
9.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Market Performance
9.5.4 F. Hoffmann-La Roche Ltd. Business Overview
9.5.5 F. Hoffmann-La Roche Ltd. Recent Developments
9.6 Genethon
9.6.1 Genethon Spinal Muscular Atrophy Medicine Basic Information
9.6.2 Genethon Spinal Muscular Atrophy Medicine Product Overview
9.6.3 Genethon Spinal Muscular Atrophy Medicine Product Market Performance
9.6.4 Genethon Business Overview
9.6.5 Genethon Recent Developments
9.7 Genzyme Corporation
9.7.1 Genzyme Corporation Spinal Muscular Atrophy Medicine Basic Information
9.7.2 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Overview
9.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Market Performance
9.7.4 Genzyme Corporation Business Overview
9.7.5 Genzyme Corporation Recent Developments
9.8 GMP-Orphan SAS
9.8.1 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Basic Information
9.8.2 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Overview
9.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Market Performance
9.8.4 GMP-Orphan SAS Business Overview
9.8.5 GMP-Orphan SAS Recent Developments
9.9 Ionis Pharmaceuticals, Inc.
9.9.1 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Basic Information
9.9.2 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Overview
9.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Market Performance
9.9.4 Ionis Pharmaceuticals, Inc. Business Overview
9.9.5 Ionis Pharmaceuticals, Inc. Recent Developments
9.10 Longevity Biotech, Inc
9.10.1 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Basic Information
9.10.2 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Overview
9.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Market Performance
9.10.4 Longevity Biotech, Inc Business Overview
9.10.5 Longevity Biotech, Inc Recent Developments
9.11 Neurodyn Inc.
9.11.1 Neurodyn Inc. Spinal Muscular Atrophy Medicine Basic Information
9.11.2 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Overview
9.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Market Performance
9.11.4 Neurodyn Inc. Business Overview
9.11.5 Neurodyn Inc. Recent Developments
9.12 Neurotune AG
9.12.1 Neurotune AG Spinal Muscular Atrophy Medicine Basic Information
9.12.2 Neurotune AG Spinal Muscular Atrophy Medicine Product Overview
9.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Product Market Performance
9.12.4 Neurotune AG Business Overview
9.12.5 Neurotune AG Recent Developments
9.13 Novartis AG
9.13.1 Novartis AG Spinal Muscular Atrophy Medicine Basic Information
9.13.2 Novartis AG Spinal Muscular Atrophy Medicine Product Overview
9.13.3 Novartis AG Spinal Muscular Atrophy Medicine Product Market Performance
9.13.4 Novartis AG Business Overview
9.13.5 Novartis AG Recent Developments
9.14 Sarepta Therapeutics, Inc.
9.14.1 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Basic Information
9.14.2 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Overview
9.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Market Performance
9.14.4 Sarepta Therapeutics, Inc. Business Overview
9.14.5 Sarepta Therapeutics, Inc. Recent Developments
9.15 Voyager Therapeutics, Inc.
9.15.1 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Basic Information
9.15.2 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Overview
9.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Market Performance
9.15.4 Voyager Therapeutics, Inc. Business Overview
9.15.5 Voyager Therapeutics, Inc. Recent Developments
9.16 Vybion, Inc.
9.16.1 Vybion, Inc. Spinal Muscular Atrophy Medicine Basic Information
9.16.2 Vybion, Inc. Spinal Muscular Atrophy Medicine Product Overview
9.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Product Market Performance
9.16.4 Vybion, Inc. Business Overview
9.16.5 Vybion, Inc. Recent Developments
9.17 WAVE Life Sciences Ltd.
9.17.1 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Basic Information
9.17.2 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Overview
9.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Market Performance
9.17.4 WAVE Life Sciences Ltd. Business Overview
9.17.5 WAVE Life Sciences Ltd. Recent Developments
10 Spinal Muscular Atrophy Medicine Market Forecast by Region
10.1 Global Spinal Muscular Atrophy Medicine Market Size Forecast
10.2 Global Spinal Muscular Atrophy Medicine Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Spinal Muscular Atrophy Medicine Market Size Forecast by Country
10.2.3 Asia Pacific Spinal Muscular Atrophy Medicine Market Size Forecast by Region
10.2.4 South America Spinal Muscular Atrophy Medicine Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Spinal Muscular Atrophy Medicine by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Spinal Muscular Atrophy Medicine Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Spinal Muscular Atrophy Medicine by Type (2025-2030)
11.1.2 Global Spinal Muscular Atrophy Medicine Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Spinal Muscular Atrophy Medicine by Type (2025-2030)
11.2 Global Spinal Muscular Atrophy Medicine Market Forecast by Application (2025-2030)
11.2.1 Global Spinal Muscular Atrophy Medicine Sales (Kilotons) Forecast by Application
11.2.2 Global Spinal Muscular Atrophy Medicine Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Spinal Muscular Atrophy Medicine Market Size Comparison by Region (M USD)
Table 5. Global Spinal Muscular Atrophy Medicine Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Spinal Muscular Atrophy Medicine Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy Medicine as of 2022)
Table 10. Global Market Spinal Muscular Atrophy Medicine Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Spinal Muscular Atrophy Medicine Sales Sites and Area Served
Table 12. Manufacturers Spinal Muscular Atrophy Medicine Product Type
Table 13. Global Spinal Muscular Atrophy Medicine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Spinal Muscular Atrophy Medicine
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Spinal Muscular Atrophy Medicine Market Challenges
Table 22. Global Spinal Muscular Atrophy Medicine Sales by Type (Kilotons)
Table 23. Global Spinal Muscular Atrophy Medicine Market Size by Type (M USD)
Table 24. Global Spinal Muscular Atrophy Medicine Sales (Kilotons) by Type (2019-2024)
Table 25. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2019-2024)
Table 26. Global Spinal Muscular Atrophy Medicine Market Size (M USD) by Type (2019-2024)
Table 27. Global Spinal Muscular Atrophy Medicine Market Size Share by Type (2019-2024)
Table 28. Global Spinal Muscular Atrophy Medicine Price (USD/Ton) by Type (2019-2024)
Table 29. Global Spinal Muscular Atrophy Medicine Sales (Kilotons) by Application
Table 30. Global Spinal Muscular Atrophy Medicine Market Size by Application
Table 31. Global Spinal Muscular Atrophy Medicine Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2019-2024)
Table 33. Global Spinal Muscular Atrophy Medicine Sales by Application (2019-2024) & (M USD)
Table 34. Global Spinal Muscular Atrophy Medicine Market Share by Application (2019-2024)
Table 35. Global Spinal Muscular Atrophy Medicine Sales Growth Rate by Application (2019-2024)
Table 36. Global Spinal Muscular Atrophy Medicine Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2019-2024)
Table 38. North America Spinal Muscular Atrophy Medicine Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Spinal Muscular Atrophy Medicine Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Spinal Muscular Atrophy Medicine Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Region (2019-2024) & (Kilotons)
Table 43. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Basic Information
Table 44. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Overview
Table 45. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Astellas Pharma Inc. Business Overview
Table 47. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine SWOT Analysis
Table 48. Astellas Pharma Inc. Recent Developments
Table 49. AveXis, Inc. Spinal Muscular Atrophy Medicine Basic Information
Table 50. AveXis, Inc. Spinal Muscular Atrophy Medicine Product Overview
Table 51. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. AveXis, Inc. Business Overview
Table 53. AveXis, Inc. Spinal Muscular Atrophy Medicine SWOT Analysis
Table 54. AveXis, Inc. Recent Developments
Table 55. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Basic Information
Table 56. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Overview
Table 57. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine SWOT Analysis
Table 59. Bioblast Pharma Ltd. Business Overview
Table 60. Bioblast Pharma Ltd. Recent Developments
Table 61. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Basic Information
Table 62. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Overview
Table 63. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Cytokinetics, Inc. 24 Business Overview
Table 65. Cytokinetics, Inc. 24 Recent Developments
Table 66. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Basic Information
Table 67. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Overview
Table 68. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. F. Hoffmann-La Roche Ltd. Business Overview
Table 70. F. Hoffmann-La Roche Ltd. Recent Developments
Table 71. Genethon Spinal Muscular Atrophy Medicine Basic Information
Table 72. Genethon Spinal Muscular Atrophy Medicine Product Overview
Table 73. Genethon Spinal Muscular Atrophy Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Genethon Business Overview
Table 75. Genethon Recent Developments
Table 76. Genzyme Corporation Spinal Muscular Atrophy Medicine Basic Information
Table 77. Genzyme Corporation Spinal Muscular Atrophy Medicine Product Overview
Table 78. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Genzyme Corporation Business Overview
Table 80. Genzyme Corporation Recent Developments
Table 81. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Basic Information
Table 82. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Overview
Table 83. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. GMP-Orphan SAS Business Overview
Table 85. GMP-Orphan SAS Recent Developments
Table 86. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Basic Information
Table 87. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Overview
Table 88. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Ionis Pharmaceuticals, Inc. Business Overview
Table 90. Ionis Pharmaceuticals, Inc. Recent Developments
Table 91. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Basic Information
Table 92. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Overview
Table 93. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Longevity Biotech, Inc Business Overview
Table 95. Longevity Biotech, Inc Recent Developments
Table 96. Neurodyn Inc. Spinal Muscular Atrophy Medicine Basic Information
Table 97. Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Overview
Table 98. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 99. Neurodyn Inc. Business Overview
Table 100. Neurodyn Inc. Recent Developments
Table 101. Neurotune AG Spinal Muscular Atrophy Medicine Basic Information
Table 102. Neurotune AG Spinal Muscular Atrophy Medicine Product Overview
Table 103. Neurotune AG Spinal Muscular Atrophy Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 104. Neurotune AG Business Overview
Table 105. Neurotune AG Recent Developments
Table 106. Novartis AG Spinal Muscular Atrophy Medicine Basic Information
Table 107. Novartis AG Spinal Muscular Atrophy Medicine Product Overview
Table 108. Novartis AG Spinal Muscular Atrophy Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 109. Novartis AG Business Overview
Table 110. Novartis AG Recent Developments
Table 111. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Basic Information
Table 112. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Overview
Table 113. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 114. Sarepta Therapeutics, Inc. Business Overview
Table 115. Sarepta Therapeutics, Inc. Recent Developments
Table 116. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Basic Information
Table 117. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Overview
Table 118. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 119. Voyager Therapeutics, Inc. Business Overview
Table 120. Voyager Therapeutics, Inc. Recent Developments
Table 121. Vybion, Inc. Spinal Muscular Atrophy Medicine Basic Information
Table 122. Vybion, Inc. Spinal Muscular Atrophy Medicine Product Overview
Table 123. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 124. Vybion, Inc. Business Overview
Table 125. Vybion, Inc. Recent Developments
Table 126. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Basic Information
Table 127. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Overview
Table 128. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 129. WAVE Life Sciences Ltd. Business Overview
Table 130. WAVE Life Sciences Ltd. Recent Developments
Table 131. Global Spinal Muscular Atrophy Medicine Sales Forecast by Region (2025-2030) & (Kilotons)
Table 132. Global Spinal Muscular Atrophy Medicine Market Size Forecast by Region (2025-2030) & (M USD)
Table 133. North America Spinal Muscular Atrophy Medicine Sales Forecast by Country (2025-2030) & (Kilotons)
Table 134. North America Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2025-2030) & (M USD)
Table 135. Europe Spinal Muscular Atrophy Medicine Sales Forecast by Country (2025-2030) & (Kilotons)
Table 136. Europe Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2025-2030) & (M USD)
Table 137. Asia Pacific Spinal Muscular Atrophy Medicine Sales Forecast by Region (2025-2030) & (Kilotons)
Table 138. Asia Pacific Spinal Muscular Atrophy Medicine Market Size Forecast by Region (2025-2030) & (M USD)
Table 139. South America Spinal Muscular Atrophy Medicine Sales Forecast by Country (2025-2030) & (Kilotons)
Table 140. South America Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2025-2030) & (M USD)
Table 141. Middle East and Africa Spinal Muscular Atrophy Medicine Consumption Forecast by Country (2025-2030) & (Units)
Table 142. Middle East and Africa Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2025-2030) & (M USD)
Table 143. Global Spinal Muscular Atrophy Medicine Sales Forecast by Type (2025-2030) & (Kilotons)
Table 144. Global Spinal Muscular Atrophy Medicine Market Size Forecast by Type (2025-2030) & (M USD)
Table 145. Global Spinal Muscular Atrophy Medicine Price Forecast by Type (2025-2030) & (USD/Ton)
Table 146. Global Spinal Muscular Atrophy Medicine Sales (Kilotons) Forecast by Application (2025-2030)
Table 147. Global Spinal Muscular Atrophy Medicine Market Size Forecast by Application (2025-2030) & (M USD)
List of Figures
Figure 1. Product Picture of Spinal Muscular Atrophy Medicine
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Spinal Muscular Atrophy Medicine Market Size (M USD), 2019-2030
Figure 5. Global Spinal Muscular Atrophy Medicine Market Size (M USD) (2019-2030)
Figure 6. Global Spinal Muscular Atrophy Medicine Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Spinal Muscular Atrophy Medicine Market Size by Country (M USD)
Figure 11. Spinal Muscular Atrophy Medicine Sales Share by Manufacturers in 2023
Figure 12. Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers in 2023
Figure 13. Spinal Muscular Atrophy Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Spinal Muscular Atrophy Medicine Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Spinal Muscular Atrophy Medicine Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Spinal Muscular Atrophy Medicine Market Share by Type
Figure 18. Sales Market Share of Spinal Muscular Atrophy Medicine by Type (2019-2024)
Figure 19. Sales Market Share of Spinal Muscular Atrophy Medicine by Type in 2023
Figure 20. Market Size Share of Spinal Muscular Atrophy Medicine by Type (2019-2024)
Figure 21. Market Size Market Share of Spinal Muscular Atrophy Medicine by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Spinal Muscular Atrophy Medicine Market Share by Application
Figure 24. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2019-2024)
Figure 25. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application in 2023
Figure 26. Global Spinal Muscular Atrophy Medicine Market Share by Application (2019-2024)
Figure 27. Global Spinal Muscular Atrophy Medicine Market Share by Application in 2023
Figure 28. Global Spinal Muscular Atrophy Medicine Sales Growth Rate by Application (2019-2024)
Figure 29. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2019-2024)
Figure 30. North America Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2023
Figure 32. U.S. Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Spinal Muscular Atrophy Medicine Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Spinal Muscular Atrophy Medicine Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2023
Figure 37. Germany Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Spinal Muscular Atrophy Medicine Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Spinal Muscular Atrophy Medicine Sales Market Share by Region in 2023
Figure 44. China Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Spinal Muscular Atrophy Medicine Sales and Growth Rate (Kilotons)
Figure 50. South America Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2023
Figure 51. Brazil Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Spinal Muscular Atrophy Medicine Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Spinal Muscular Atrophy Medicine Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Spinal Muscular Atrophy Medicine Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Spinal Muscular Atrophy Medicine Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Spinal Muscular Atrophy Medicine Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Spinal Muscular Atrophy Medicine Market Share Forecast by Type (2025-2030)
Figure 65. Global Spinal Muscular Atrophy Medicine Sales Forecast by Application (2025-2030)
Figure 66. Global Spinal Muscular Atrophy Medicine Market Share Forecast by Application (2025-2030)
